TRML Tourmaline Bio Inc

 Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the formation of its Cardiovascular Scientific Advisory Board (CV SAB). The CV SAB is expected to provide strategic guidance and expertise as Tourmaline advances its pacibekitug cardiovascular diseases program, including the TRANQUILITY Phase 2 clinical trial that commenced earlier this year and for which Tourmaline continues to expect topline data in the first half of 2025.

The CV SAB brings together academic and industry veterans with significant experience in cardiovascular medicine, clinical trial design and execution, and therapeutic innovation. Their insights and guidance are expected to be instrumental in shaping the strategic direction of Tourmaline’s cardiovascular program as the company prepares for Phase 3 clinical trial readiness in 2025, supporting efforts to redefine standards of care for high-risk cardiovascular disease patients.

Cardiovascular Scientific Advisory Board Members:

• Joshua Beckman, MD, MSc – UT Southwestern Medical Center
• Marc Bonaca, MD, MPH – University of Colorado, CPC Clinical Research
• Robin Choudhury, MA, DM, FRCP – University of Oxford
• Douglas L. Mann, MD – Washington University School of Medicine
• James Min, MD – Cleerly, Inc.
• Pradeep Natarajan, MD, MMSc – Massachusetts General Hospital
• Michael D. Shapiro, DO, MCR – Wake Forest University School of Medicine
• Michael Szarek, PhD – University of Colorado, CPC Clinical Research

“We are honored to welcome such a distinguished group of experts to our Cardiovascular Scientific Advisory Board,” said Emil deGoma, MD, Senior Vice President of Medical Research at Tourmaline. “The depth and breadth of their collective expertise across atherosclerotic cardiovascular disease (ASCVD), heart failure, vascular medicine, imaging, genetics, and biostatistics will be invaluable as we advance pacibekitug for cardiovascular diseases. A growing body of evidence continues to support the therapeutic potential of IL-6 inhibition in ASCVD and beyond.”

For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com.

About Tourmaline BioTourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).

About Pacibekitug Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing pacibekitug in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration.

Cautionary Note Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe,” “designed to,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Tourmaline’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of pacibekitug; the timing of initiation, progress and results of Tourmaline’s current and future clinical trials for pacibekitug, including reporting of data therefrom; the timing of Phase 3 clinical trial readiness; and the timing and potential to expand pacibekitug into additional indications. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Tourmaline’s current or future product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Tourmaline’s current or future product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Tourmaline’s current or future product candidates; the risk that Tourmaline’s current or future product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Tourmaline anticipates; risks regarding the accuracy of Tourmaline’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts of macroeconomic conditions Tourmaline’s business, clinical trials and financial position; and other risks and uncertainties that are described in Tourmaline’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on August 8, 2024 and other filings that Tourmaline makes with the SEC from time to time. Any forward-looking statements speak only as of the date of this press release and are based on information available to Tourmaline as of the date hereof, and Tourmaline assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media ContactScient PRSarah MishekSMishek@ScientPR.com  

Investor ContactMeru AdvisorsLee M. Sternlstern@meruadvisors.com